论文部分内容阅读
目的分析甘露聚糖肽联合顺铂胸腔内灌注治疗恶性胸腔积液的疗效及安全性。方法选择2014年1月至2015年2月恶性胸腔积液患者84例,随机分成对照组和治疗组,每组42例。对照组患者单独采用顺铂胸腔内灌注治疗,治疗组患者采用甘露聚糖肽联合顺铂胸腔内灌注治疗,观察两组患者的疗效及治疗安全性。结果治疗组患者的疗效及生活质量均明显优于对照组,不良反应发生率明显低于对照组,差异均有统计学意义(P<0.05)。结论对恶性胸腔积液患者采用甘露聚糖肽联合顺铂胸腔内灌注治疗能有效提高其疗效及生活质量,且安全性较高,可作为恶性胸腔积液治疗的首选治疗方法。
Objective To analyze the efficacy and safety of intrapleural perfusion of mannan and cisplatin in the treatment of malignant pleural effusion. Methods From January 2014 to February 2015, 84 patients with malignant pleural effusion were randomly divided into control group and treatment group, 42 cases in each group. Patients in the control group were treated with intraperitoneal injection of cisplatin alone. The patients in the treatment group were treated with intraperitoneal infusion of mannan plus cisplatin, and the curative effect and safety of the two groups were observed. Results The curative effect and quality of life in the treatment group were significantly better than those in the control group, and the incidence of adverse reactions was significantly lower than that in the control group (P <0.05). Conclusions The treatment of malignant pleural effusion with mannan plus cisplatin intrapleural infusion therapy can effectively improve the efficacy and quality of life, and high safety, and can be used as the preferred treatment for malignant pleural effusion.